Trial · NCT02761187
Outcomes28
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Co-morbidities | Baseline up to 5 years | All Enrolled Population included all participants who signed the inform consent form. Overall number of participants analyzed is the number of participants available for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Diagnosed With Newly Diagnosed Multiple Myeloma (NDMM) and Relapsed/Refractory Multiple Myeloma (R/RMM) | At Baseline | All Enrolled Population included all participants who signed the inform consent form. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Diagnosed With Symptoms of ND MM and R/R MM During the Study | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. | ||
| PRIMARY | Sites of Disease Diagnosed With ND MM and R/R MM | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. | ||
| PRIMARY | Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status | At Baseline | All Enrolled Population included all participants who signed informed consent. Overall number of participants analyzed is the number of participants available for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Myeloma Frailty Index | At Baseline | All Enrolled Population included all participants who signed the inform consent form. Overall number of participants analyzed is the number of participants available for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Evaluated for Minimal Residual Disease (MRD) | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. | ||
| PRIMARY | Number of Participants Evaluated for Gene Expression Profiling (GEP) | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. | ||
| PRIMARY | Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) | At Baseline | All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage | At Baseline | All Enrolled Population included all participants who signed informed consent. Overall number of participants are the number of participants available for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Duration of Treatment for Participants With and Without Stem Cell Transplant | Baseline up to 5 years | All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. Overall number analyzed are the number of participants with data available for analyses. The data is reported as per the known line of therapies. | months | MEDIAN |
| PRIMARY | Overall Survival (OS) | Baseline up to 5 years | All Enrolled Population, included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis. | months | MEDIAN |
| PRIMARY | Disease Progression Status on Each Regimen | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. | ||
| PRIMARY | Response to Each Regimen | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. | ||
| PRIMARY | Time to Next Therapy | Baseline up to 5 years | All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis. | months | MEDIAN |
| PRIMARY | Number of Participants With Stem Cell Transplant | Baseline up to 5 years | All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Receiving Different Treatment Combinations | Baseline up to 5 years | All Enrolled Population included all participants who signed the inform consent form. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd 3rd and 4th line of therapy. The overall number of participants analyzed is the number of participants available for analyses. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Treatment Sequencing | Baseline up to 5 years | All Enrolled Population included all participants who signed informed consent. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd and 3rd line of therapy. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants in the Treatment Rechallenge | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. | ||
| SECONDARY | Number of Clinical Outcomes for Different Strategies | Baseline up to 5 years | As the study was early terminated data was not collected for this outcome measure. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02761187/outcomes